US FDA panel rejects maintenance use of OSI/Roche's Tarceva
This article was originally published in Scrip
The US FDA's oncologic drugs advisory panel has rejected a maintenance indication for OSI Pharmaceuticals/Roche's EGFR-targeted small molecule drug Tarceva (erlotinib) in non-small cell lung cancer (NSCLC).
You may also be interested in...
Clinical Trials: Industry Navigating Alternative Ways Of Delivering Investigational Drugs During Pandemic
New approaches include delivering study drug from a clinical site directly to a patient’s house through a courier service, as well as use of drones and automated dispensing units; future trials could see a mix of delivery approaches.
Benefits of the BCMA-directed antibody-drug conjugate outweigh its ocular risks in heavily pretreated multiple myeloma patients, Oncologic Drugs Advisory Committee says at the conclusion of a virtual meeting beset by technical problems.
Heading into an advisory committee review, agency suggests belantamab’s risks of keratopathy and other ocular issues have not been fully characterized and questions whether the proposed mitigation measures, including dosing modifications, are adequate.